Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 9/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.36 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.36 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.35 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5482086 | 0.85 | P2RY12 (0.37) | P2RY12PRMT6P2RY2P2RY1P2RY6 | |
| SCHEMBL17231772 | 0.85 | P2RY12 (0.37) | P2RY12PRMT6P2RY2P2RY1P2RY6 | |
| SCHEMBL5490977 | 0.84 | POLB (0.36) | P2RY6 | |
| SCHEMBL17272943 | 0.83 | POLB (0.49) | P2RY12P2RY2P2RY6 | |
| SCHEMBL5925300 | 0.82 | TYMP (0.39) | P2RY12PRMT6 | |
| SCHEMBL8666792 | 0.81 | P2RY12 (0.44) | P2RY12PRMT6P2RY2P2RY1P2RY6 | |
| SCHEMBL7516040 | 0.81 | P2RY12 (0.44) | P2RY12PRMT6P2RY2P2RY1P2RY6 | |
| SCHEMBL19771221 | 0.81 | P2RY12 (0.43) | P2RY12PRMT6P2RY2P2RY1P2RY6 | |
| SCHEMBL19767623 | 0.81 | P2RY12 (0.43) | P2RY12PRMT6P2RY2P2RY1P2RY6 | |
| SCHEMBL17283109 | 0.81 | P2RY12 (0.43) | P2RY12PRMT6P2RY2P2RY1P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070117773-A1 | Telomerase-inhibiting ENA oligonucleotide | SANKYO COMPANY, LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| EP-1783216-A1 | TELOMERASE-INHIBITORY ENA OLIGONUCLEOTIDE | Sankyo Company, Limited (JP) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117773-A1 | Telomerase-inhibiting ENA oligonucleotide | TERT, ENO1, TERB1 | P2RY12 1500/4885PRMT6 2148/4885P2RY2 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.